MMV Call for proposals: Drug discovery
The Medicines for Malaria Venture (MMV) is calling for proposals for Drug discovery. MMV works to bring forward lifesaving medicines and foster a brighter future.
Topic Areas:
1. Compounds having activity against Plasmodium falciparum blood stages in vitro (TCP1-TPP1) for use in treatment or chemoprevention (TCP1-TPP2)
2. Compounds addressing the key priorities of the malaria eradication agenda (TCP3, and TCP6). Novel chemical series with asexual blood stage EC50<500nM and which have one or more of the following key features:
- A known, novel mechanism of action without cross resistance to clinical or marketed antimalarials. Priority will be given to mechanisms that are not represented in the MMV portfolio.
- An inability to select resistant mutants in vitro after at least 60 days’ incubation with compound
- Potency on early stage gametocytes similar to that for asexual blood stages
- Potency on stage V gametocytes (TCP5) similar to that for asexual blood stages and evidence of transmission blocking to the mosquito
- Potency on P. falciparum liver stages similar to that for asexual blood stages
- A long half-life (ideally >4h in rodents) and confirmed in vivo efficacy. Compound series with very long rodent half-lives (>10h) are of particular interest.For advanced series, we are seeking novel compounds with, ideally, a predicted human half-life >100h and a predicted oral single human dose <500mg
3. Novel families of molecules in the hit-to-lead or lead optimization stages, without G6PD deficiency liabilities that either:
- kill or reactivate hypnozoites for use as part of a P. vivax radical cure;
or
- have oral endectocide activity suggesting human single monthly dose <100mgs
Read more here.
Application deadline March 31, 2023.
